ArticleMedicine2024

Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma.

Ryoichi Miura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.